Designing Longevity
Skip to main content
Moderate EvidencePeptide

Eloralintide

Selective amylin receptor agonist

Last updated: November 2026
Share:

Eloralintide is an investigational peptide that acts on the amylin pathway and is being studied for weight management. A randomized phase 2 study in adults with obesity or overweight without type 2 diabetes found greater weight reduction with eloralintide than with placebo at 48 weeks. The study used several trial groups. Its results describe the tested medicine, population and follow-up period.

Evidence Level: Moderate Evidence

Some human data, strong animal studies, plausible mechanism

Regulatory Status: Investigational. No FDA-approved product for weight management was identified in this review.

How It Works

Amylin signaling plays a role in how full people feel after eating. Researchers are testing whether medicines that act on this pathway can support sustained weight reduction.

Potential Benefits

  • A randomized phase 2 study in adults with obesity or overweight without type 2 diabetes found greater weight reduction with eloralintide than with placebo at 48 weeks.

Risks & Considerations

  • A trial result applies to the preparation and people studied. Long-term benefits and harms still need study. Results from separate trials cannot establish which medicine works better.

Key Research

Eloralintide for the treatment of obesity

The Lancet, 2025

A randomized phase 2 study in adults with obesity or overweight without type 2 diabetes found greater weight reduction with eloralintide than with placebo at 48 weeks.

View Study

Frequently Asked Questions

Is eloralintide FDA-approved for weight management?

No FDA-approved product for this use was identified. The evidence on this page describes study preparations.

How does this fit alongside other weight medicines?

It acts on the amylin pathway. The category comparison links to the studied or approved use for each medicine and explains what readers can compare.

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated November 2026.

Found this helpful? Share it or save it for later.

Share:

See a problem or outdated information? Tell us.